{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=22",
    "query": {
      "condition": "Phase 1 Clinical Trial",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 9283,
    "total_pages": 929,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:48:36.008Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00100347",
      "title": "Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma,",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PPI-2458",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PRAECIS Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2004-12",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-07-25",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 8,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Albuquerque, New Mexico + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100347"
    },
    {
      "nct_id": "NCT00006348",
      "title": "Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Nausea and Vomiting",
        "Precancerous Condition",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ondansetron",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "2000-10",
      "completion_date": "2001-09",
      "has_results": false,
      "last_update_posted_date": "2016-07-06",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006348"
    },
    {
      "nct_id": "NCT05514717",
      "title": "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER2-positive Non-Small Cell Lung Cancer",
        "HER2-positive Colorectal Cancer",
        "HER2-positive Tumors",
        "HER2 Low Breast Cancer"
      ],
      "interventions": [
        {
          "name": "XMT-2056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Day One Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2023-01-24",
      "completion_date": "2026-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Stanford, California • Celebration, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514717"
    },
    {
      "nct_id": "NCT03646240",
      "title": "ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy Intractable"
      ],
      "interventions": [
        {
          "name": "ABI-009",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "3 Years to 26 Years"
      },
      "enrollment_count": 14,
      "start_date": "2018-07-31",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03646240"
    },
    {
      "nct_id": "NCT03500991",
      "title": "HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Central Nervous System Tumor, Pediatric",
        "Glioma",
        "Ependymoma",
        "Medulloblastoma",
        "Germ Cell Tumor",
        "Atypical Teratoid/Rhabdoid Tumor",
        "Primitive Neuroectodermal Tumor",
        "Choroid Plexus Carcinoma",
        "Pineoblastoma"
      ],
      "interventions": [
        {
          "name": "HER2-specific chimeric antigen receptor (CAR) T cell",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "1 Year to 26 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-07-26",
      "completion_date": "2039-07-26",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03500991"
    },
    {
      "nct_id": "NCT04018274",
      "title": "Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06651600",
          "type": "DRUG"
        },
        {
          "name": "Ethinyl estradiol (EE) and levonorgestrel(LN)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2019-08-09",
      "completion_date": "2019-10-16",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 2,
      "location_summary": "Coral Gables, Florida • Miami, Florida",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04018274"
    },
    {
      "nct_id": "NCT05130255",
      "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SCLC",
        "Malignant Melanoma",
        "Sarcoma",
        "High Risk Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi)",
          "type": "DRUG"
        },
        {
          "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi)",
          "type": "DRUG"
        },
        {
          "name": "GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)",
          "type": "DRUG"
        },
        {
          "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi)",
          "type": "DRUG"
        },
        {
          "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi)",
          "type": "DRUG"
        },
        {
          "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi)",
          "type": "DRUG"
        },
        {
          "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Y-mAbs Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2022-11-17",
      "completion_date": "2026-03-11",
      "has_results": true,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05130255"
    },
    {
      "nct_id": "NCT06171178",
      "title": "A Study of ASP1012 in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ASP1012",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-05-15",
      "completion_date": "2025-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06171178"
    },
    {
      "nct_id": "NCT00826085",
      "title": "Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ThermoDox in combination with Microwave Hyperthermia (heat)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Imunon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2013-02",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Newnan, Georgia • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00826085"
    },
    {
      "nct_id": "NCT06469385",
      "title": "Topical ENS-002 for Atopic Dermatitis in Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Atopic Dermatitis Eczema"
      ],
      "interventions": [
        {
          "name": "ENS-002",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Concerto Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2024-09-18",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-11-19T08:48:36.008Z",
      "location_count": 3,
      "location_summary": "Hollywood, Florida • Beverly, Massachusetts • Austin, Texas",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Beverly",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06469385"
    }
  ]
}